Avedro, Inc. is a commercial-stage ophthalmic medical technology company. The Company is focused on treating corneal ectatic disorders. Its Avedro Corneal Remodeling Platform is designed to stabilize and reshape the cornea utilizing corneal cross-linking in minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct refractive conditions. Its platform consists of KXL and Mosaic systems, which delivers ultraviolet A, light and a suite of single-use riboflavin drug formulations. Its KXL system is marketed to perform other corneal cross-linking procedures, such as Lasik Xtra. It offers Mosaic System for Photorefractive Intrastromal Cross-Linking (PiXL), Lasik Xtra and Accelerated Cross-Linking; KXL System for Lasik Xtra and Accelerated Cross-Linking, and Riboflavin Family for customizing each cross-linking procedures. The Company sells its products to ophthalmologists, hospitals and ambulatory surgery centers.